EP2413696A4 - Zusammensetzung zur behandlung von morbus alzheimer - Google Patents

Zusammensetzung zur behandlung von morbus alzheimer

Info

Publication number
EP2413696A4
EP2413696A4 EP10759174A EP10759174A EP2413696A4 EP 2413696 A4 EP2413696 A4 EP 2413696A4 EP 10759174 A EP10759174 A EP 10759174A EP 10759174 A EP10759174 A EP 10759174A EP 2413696 A4 EP2413696 A4 EP 2413696A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10759174A
Other languages
English (en)
French (fr)
Other versions
EP2413696A1 (de
Inventor
Jorge Galvez
Javier Llompart
David Land
Giulio Pasinetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Medisyn Technologies Inc
Original Assignee
Medisyn Technologies Inc
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medisyn Technologies Inc, Mount Sinai School of Medicine filed Critical Medisyn Technologies Inc
Publication of EP2413696A1 publication Critical patent/EP2413696A1/de
Publication of EP2413696A4 publication Critical patent/EP2413696A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10759174A 2009-04-03 2010-04-05 Zusammensetzung zur behandlung von morbus alzheimer Withdrawn EP2413696A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21182109P 2009-04-03 2009-04-03
PCT/US2010/001041 WO2010114636A1 (en) 2009-04-03 2010-04-05 Compositions for treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2413696A1 EP2413696A1 (de) 2012-02-08
EP2413696A4 true EP2413696A4 (de) 2012-10-24

Family

ID=42828621

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10759174A Withdrawn EP2413696A4 (de) 2009-04-03 2010-04-05 Zusammensetzung zur behandlung von morbus alzheimer

Country Status (4)

Country Link
EP (1) EP2413696A4 (de)
AU (1) AU2010232923A1 (de)
CA (1) CA2759187A1 (de)
WO (1) WO2010114636A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2731608T (pt) * 2011-07-13 2018-06-04 Microbiotix Inc Inibidores do sistema de secreção tipo iii bacteriano
CN102391262A (zh) * 2011-07-20 2012-03-28 延边大学 含3-羧烷基罗丹宁衍生物的抗菌化合物
WO2014186450A2 (en) * 2013-05-14 2014-11-20 The Board Of Regents Of The University Of Texas System Highly potent inhibitors of porcupine
WO2022120150A1 (en) * 2020-12-03 2022-06-09 Duke University Amiloride derivatives and methods of using same for the treatment of viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001455A1 (de) * 1990-07-25 1992-02-06 Luedke Hans Werner Arzneimittel gegen degenerative hirnleistungsstörungen vom alzheimerschen typ und cholinerge systemstörungen
WO2003070737A1 (en) * 2002-02-21 2003-08-28 Polimeri Europa S.P.A. Nickel tris-pyrazolyl borate complexes and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599515B2 (en) * 1987-09-16 1990-07-19 Taiho Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
EP0361489A3 (de) * 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha 3,4-Diaminochinolin- und Pyridinverbindungen
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
AU711211B2 (en) * 1994-04-06 1999-10-07 Sumitomo Chemical Company, Limited Alpha-substituted phenylacetic acid derivative, process for producing the same, and agricultural bactericide containing the same
DE19548146C1 (de) * 1995-12-21 1997-11-20 Basf Ag Tris(pyrazolyl)boratmetallkomplex-Katalysatoren und deren Verwendung
ES2203988T3 (es) * 1997-11-06 2004-04-16 Smithkline Beecham Plc Compuestos de pirimidinona y composiciones farmaceuticas que los contienen.
ATE251613T1 (de) * 1998-08-21 2003-10-15 Smithkline Beecham Plc Pyrimidinonderivate zur behandlung von atheroscleros
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
JP2007500128A (ja) * 2003-07-25 2007-01-11 アムジエン・インコーポレーテツド 置換複素環式化合物及び使用方法
MXPA06012510A (es) * 2004-04-28 2006-12-15 Pfizer Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
US7718683B2 (en) * 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
EP2160389B1 (de) * 2007-04-18 2014-03-12 Probiodrug AG Thioxochinazolinonderivate als inhibitoren von glutaminylcyclase
PE20090445A1 (es) * 2007-07-16 2009-05-18 Wyeth Corp Inhibidores de produccion de beta amiloide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001455A1 (de) * 1990-07-25 1992-02-06 Luedke Hans Werner Arzneimittel gegen degenerative hirnleistungsstörungen vom alzheimerschen typ und cholinerge systemstörungen
WO2003070737A1 (en) * 2002-02-21 2003-08-28 Polimeri Europa S.P.A. Nickel tris-pyrazolyl borate complexes and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010114636A1 *

Also Published As

Publication number Publication date
AU2010232923A1 (en) 2011-11-03
EP2413696A1 (de) 2012-02-08
WO2010114636A1 (en) 2010-10-07
CA2759187A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (de) Pharmazeutische zusammensetzung zur behandlung von morbus alzheimer
EP2382176A4 (de) Verwendung von stickstoffhaltigen kurkuminanaloga zur behandlung von alzheimer-krankheit
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EP2312945A4 (de) Purinderivate zur behandlung von morbus alzheimer
IL213259A0 (en) Composition for the use to treat alzheimer's disease
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
HK1169941A1 (zh) 治療外周血管疾病的組合物
EP2707369A4 (de) Zusammensetzung und verfahren zur behandlung von morbus alzheimer
IL200342A (en) A drug used to treat cartilage disease
EP2268647A4 (de) Verbindungen und zusammensetzungen für den nachweis und die behandlung von morbus alzheimer und verwandten erkrankungen
EP2312946A4 (de) Pyrimidinderivate zur behandlung von morbus alzheimer
EP2485733A4 (de) Verfahren zur behandlung von morbus alzheimer
EP2429992A4 (de) Behandlung von leichter kognitiver beeinträchtigung und morbus alzheimer
EP2378879A4 (de) Triazolderivate für die behandlung von morbus alzheimer
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
PT2429507T (pt) Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
EP2568811A4 (de) Behandlung von leichter kognitiver beeinträchtigung und morbus alzheimer
EP2379075A4 (de) Triazol-derivate zur behandlung von alzheimer-krankheit
EP2398789A4 (de) Spiropyrrolidinderivate als beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit
EP2349308A4 (de) Verbindungen zur behandlung von morbus alzheimer
EP2413696A4 (de) Zusammensetzung zur behandlung von morbus alzheimer
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2391379A4 (de) Verbindungen und verfahren zur behandlung von morbus alzheimer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MOUNT SINAI SCHOOL OF MEDICINE

Owner name: MEDISYN TECHNOLOGIES, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/69 20060101ALI20120920BHEP

Ipc: A61P 25/28 20060101ALI20120920BHEP

Ipc: A61K 31/415 20060101ALI20120920BHEP

Ipc: A61K 31/4709 20060101ALI20120920BHEP

Ipc: A61K 31/513 20060101ALI20120920BHEP

Ipc: A01N 43/64 20060101AFI20120920BHEP

Ipc: A61K 31/426 20060101ALI20120920BHEP

Ipc: A61K 31/4196 20060101ALI20120920BHEP

Ipc: A61K 31/404 20060101ALI20120920BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130426